Northwest Biotherapeutics (STU:NBYB) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NBYB Northwest Biotherapeutics Inc STU:NBYB
17 GF Score
Price €0.15
GF Value €0.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Northwest Biotherapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

STU:NBYB vs LCTX, VRXA, ABEO: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Northwest Biotherapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Margin of Safety % (DCF Dividends Based) falls into.


STU:NBYB
17GF Score
Northwest Biotherapeutics Inc STU:NBYB
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Northwest Biotherapeutics (STU:NBYB) Overvalued in 2026?

Based on GuruFocus' analysis, Northwest Biotherapeutics stock appears to be undervalued. The current stock price of €0.15 is trading 37.5% below its estimated GF Value™ of €0.24. GuruFocus considers Northwest Biotherapeutics to be Possible Value Trap.

Key valuation signals for STU:NBYB:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €0.24 vs. price of €0.15 (37.5% below fair value)
  • GF Score™: 17/100 with 5 warning signs

No single metric tells the full story. See the STU:NBYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Northwest Biotherapeutics Business Description

Other Exchanges NWBO:USA
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score

Get the complete analysis for STU:NBYB

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.24
GF Value